Largest-Ever Precision Medicine Oncology Trial Ready for Launch

Anita T. Shaffer @Shaffer1
Published: Monday, Jun 01, 2015

Doroshow described the planning and ultimately the conduct of NCI-MATCH as a national effort. “It has taken an absolute village to build this trial,” he said. “Hundreds of people supported the launch of the trial so far. Ultimately, it will take thousands of investigators to execute this study.”

The ECOG-ACRIN Cancer Research Group, which was formed three years ago through the merger of two oncology research organizations, is partnering with the NCI to plan and carry out the study at 2400 sites nationwide.

One of the army of investigators who will be involved in NCI-MATCH is Juneko Grilley-Olson, MD, an assistant professor at UNC Lineberger Comprehensive Cancer Center in North Carolina who specializes in thoracic and bone and soft tissue oncology.

She will help lead a substudy involving the investigational PI3K inhibitor GDC-0032, also called taselisib, which is expected to be studied in the second wave of trials that start as NCI-MATCH expands. Patients whose tumors harbor a PIK3CA mutation without a KRAS mutation and without PTEN loss are candidates for the study, Grilley-Olson said in an interview.

Grilley-Olson noted that NCI-MATCH organizers are hoping that at least 25% of the patients who enroll in studies have rare cancers.

“Those are tumors that often don’t have dedicated trials,” she said. “In the PI3 kinase arm we would be looking to enrich it for rarer tumors that have not been as extensively studied. With tumors such as breast cancer or lung cancer we probably wouldn’t learn as much additional information in a 30-patient cohort because they have been studied in trials with hundreds and hundreds of people [in those cancers].”

For more information about the NCI-MATCH trial, visit http://goo.gl/EEzHSD.

<<< View more from the 2015 ASCO Annual Meeting




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Year in Review™: Reflecting on Recent Evidence for the Treatment of Hematologic MalignanciesFeb 28, 20192.0
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Publication Bottom Border
Border Publication
x